Pertuzumab/trastuzumab - Roche

Drug Profile

Pertuzumab/trastuzumab - Roche

Alternative Names: RG 6264

Latest Information Update: 13 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Dimerisation inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 04 Jun 2018 Phase-III clinical trials in Breast cancer (Combination therapy, Early-stage disease) in Italy, Belgium (SC) (EudraCT2017-004897-32) (NCT03493854 )
  • 11 Apr 2018 Roche plans a phase III trial for Breast cancer (Combination therapy, Early stage disease) in USA, Argentina, Brazil, Canada, Czechia, Germany, South Korea, Mexico, Mexico, Russia, Taiwan, Thailand, Turkey, Ukraine and United Kingdom, (NCT03493854)
  • 21 Feb 2018 Phase-I clinical trials in Breast cancer (Early-stage disease, Combination therapy) in Switzerland (SC), prior to February 2018 (Roche pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top